1 completed, 1 terminated, 1 withdrawn. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
| Selinexor Combination Ph 1 Study Selinexor, Irinotecan - Solid Tumor Malignancy | Phase 1 / Phase 2 | Withdrawn | Martin Gutierrez | 2014-09-01 | 2022-01-04 |
Acrocephalosyndactylia (1) · Hematologic Neoplasms (1) · Leukemia (1) · Lymphoma (1) · Multiple Myeloma (1)
Blood Protein Disorders (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Craniofacial Abnormalities (1) · Craniosynostoses (1) · Dysostoses (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1)
2019-nCoV Vaccine mRNA-1273 (1) · Anti-Bacterial Agents (1) · Antiemetics (1) · Antifungal Agents (1) · Electrocardiography (1) · Irinotecan (1) · RNA, Messenger (1) · pemigatinib (1) · selinexor (1)
Incyte Corporation (1) · Martin Gutierrez (1) · National Cancer Institute (NCI) (1)
United States (3) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
James Gulley, M.D. (1) · Peter Langmuir, MD (1)
2018 (1)